Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation

Background. Despite improved surgical techniques and medical management, primary graft dysfunction ( PGD) remains a major cause of early morbidity and mortality after lung transplantation. Different types of lung preservation solutions have been developed and applied to clinical use; however, the relative clinical efficacy of these solutions to prevent PGD remains controversial. This study aimed to investigate the effect of the three solutions most commonly used ( Perfadex [ Vitrolife, Goteborg, Sweden], Papworth, and Euro-Collins [ Baxter Healthcare, Old Toongabbie NSW, Australia]) on posttransplant outcomes. Methods. Early outcomes from 157 consecutive lung transplants ( 113 bilateral and 44 single) performed at The Alfred Hospital were compared across three preservation solutions. Results. Posttransplant oxygenation ( p = 0.57), pulmonary vascular resistance ( p = 0.34), intubation hours ( p = 0.66), intensive care unit days ( p = 0.34), severe PGD ( grade 3) ( p = 0.70), 30-day mortality ( p = 0.87), and 3-month % predicted forced expiratory volume in 1 second ( p = 0.58) were not statistically different; however, Perfadex trended toward superiority among the three solutions. After adjustment of donor, recipient, and operative factors in multivariate analysis, Perfadex was significantly associated with the prevention of moderate to severe PGD ( grade 2 to 3) at 48 hours posttransplant ( odds ratio = 0.26 [ 0.10 to 0.72], p < 0.01) compared with Papworth ( odds ratio = 0.75 [ 0.32 to 1.75], p = 0.51) and Euro-Collins ( reference) solutions. Conclusions. Although any advantageous effects of Perfadex on early posttransplant outcomes were generally subtle and statistically nonsignificant, Perfadex prevented moderate to severe PGD. Switching preservation solution from Euro-Collins ( or Papworth) to Perfadex would appear to usefully contribute to a strategy to reduce PGD in lung transplantation.